Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
99mTc-labeled HER2 affibody
- Development stage
- Phase 1
- Lead developer
- Affibody
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
A radiopharmaceutical composed of a small engineered protein (affibody) that specifically binds to human epidermal growth factor receptor type 2 (HER2), labeled with the gamma-emitting radionuclide technetium-99m (99mTc). The HER2 affibody is a non-immunoglobulin scaffold protein (~6.5–7 kDa) designed for high-affinity and selective binding to HER2 receptors overexpressed in certain cancers such as breast cancer. Upon intravenous administration, the radiolabeled affibody binds to HER2-expressing tumor cells and enables their detection by single-photon emission computed tomography (SPECT) imaging. This allows for non-invasive assessment of HER2 status in tumors and metastases to guide targeted therapy decisions[1][3][4][6][8]. Multiple variants exist based on different chelators or sequence modifications but share the same core mechanism.
- Other names
- technetium Tc-99m anti-HER2 affibodytechnetium Tc-99m anti-HER2 affibody HPArk2technetium Tc-99m anti-HER2 affibody ABH2
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on 99mTc-labeled HER2 affibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 99mTc-labeled HER2 affibody.